Reata Pharmaceuticals, Inc. (RETA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA). Investors who purchased Reata securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Reata has violated federal securities laws.
On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin. On this news, Reata’s stock price fell $14.99 per share or 14.23%, to close at $90.38 per share on May 10, 2023.
If you are aware of any facts relating to this investigation or purchased Reata shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.